Fecal Microbiota Transplantation for the Treatment of Obesity

Exclusion Criteria

• •1. Triglycerides \> 500 mg/dL
• •2. Use of antibiotics \<8 weeks prior to participation
• •3. Use of probiotics \<4 weeks prior to participation
• •4. Alcohol use of greater than 20g/daily or suspicion of alcohol abuse and dependence
• •5. Substance abuse, current
• •6. LFTS greater then 3x the ULN
• •7. Cirrhosis.
• •8. DM type 2 that is insulin dependent, treated with GLP1-agonists, or poorly controlled on oral medications (HbA1C \> 10%)
• •9. Use of any weight loss medication or participation in a weight loss study or program such as Weight Watchers
• •10. History of recent weight change (weight loss or weight gain in the two months preceding trial enrollment). This is defined as a gain or loss of 10 or more pounds in the preceding 2 months
• •11. Patients who are pregnant or breastfeeding
• •12. Patients who are unable to give informed consent
• •14\. Patients who have previously undergone FMT 15. Patients who have a confirmed malignancy or cancer 16. Patients who are immunocompromised 17. Participation in a clinical trial in the preceding 30 days or simultaneously during this trial 18. Previous gastric or small intestinal surgery that alters gut anatomy such as fundoplication, gastric resection, gastric bypass, small bowel resection, and ileocectomy 19. Other comorbidities including: systemic lupus, inflammatory bowel disease, or Chronic kidney disease as defined by a GFR \<60mL/min/1.73m2 44 20. History of rheumatic heart disease, endocarditis, or valvular disease due to risk of bacteremia 21. Any condition, based on clinical judgment that may make study participation unsafe 22. History of severe food allergies 23. Use of immune modulators including methotrexate, mycophenolate mofetil, tacrolimus, cyclosporine, thalidomide, Interleukin-10, or Interleukin-11 24.Treatment with infliximab, adalimumab, certolizumab, natalizumab, vedolizumab or thalidomide 25. Congenital or acquired immunodeficiencies